Roman Dbdr Acquisition Corp. Ii (DRDB) Stock Price & Analysis
Roman Dbdr Acquisition Corp. Ii (DRDB) fell 0.09% to USD 10.52 as of June 11, 2026 at 02:17 UTC, according to Nexqual real-time market data.
DRDB last closed at USD 10.53; the session ranged USD 10.52–10.53 on volume of 79,319 shares. Market capitalization is $322.61M, with a 52-week range of USD 10.23–10.56 (NGM). Source: Nexqual, June 11, 2026 at 02:17 UTC.
Key Statistics (as of June 11, 2026 at 02:17 UTC)
| Price | USD 10.52 |
|---|---|
| Change | ▼ 0.09% (down) |
| Previous Close | USD 10.53 |
| Open | USD 10.53 |
| Day Range | USD 10.52 – 10.53 |
| 52-Week Range | USD 10.23 – 10.56 |
| Volume | 79,319 shares |
| Market Cap | $322.61M |
| Exchange | NGM |
Technical Analysis (DRDB)
Nexqual's technical model rates DRDB "NEUTRAL" based on 3 bullish and 2 bearish signals across 124 daily candles, as of June 11, 2026 at 02:17 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 46.81 (neutral) |
| vs SMA50 | Above (USD 10.52) |
| MACD | 0 (positive) |
Analyst Ratings (DRDB)
Wall Street analysts rate DRDB "None", per Nexqual as of June 11, 2026 at 02:17 UTC.
| Consensus Rating | None |
|---|
Earnings (DRDB)
Source: Nexqual, June 11, 2026 at 02:17 UTC.
Financials & Fundamentals (DRDB)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.09 |
| Total Cash | $53,490 |
| Total Debt | $480,070 |
Source: Nexqual, June 11, 2026 at 02:17 UTC.
Financial Health Score (DRDB)
Nexqual rates Roman Dbdr Acquisition Corp. Ii's overall financial health "Weak" across five dimensions, as of June 11, 2026 at 02:17 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $53K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$1M |
| Efficiency | Mixed — No data |
Ownership (DRDB)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +108.94% |
| Shares Outstanding | 23.00M |
| Float | 21.28M |
| Short % of Float | +0.00% |
Source: Nexqual, June 11, 2026 at 02:17 UTC.
Leadership (DRDB)
Roman Dbdr Acquisition Corp. Ii is led by Dixon R. Doll (age 57), CEO & Chairman of the Board, per Nexqual as of June 11, 2026 at 02:17 UTC.
| CEO & Chairman of the Board | Dixon R. Doll (age 57) |
|---|---|
| CFO and Principal Accounting & Financial Officer | John J. Birmingham (age 51) |
| Chief Technology Officer | Al Basseri |
Major Backers & Investors (DRDB)
Notable institutional backers of Roman Dbdr Acquisition Corp. Ii include Berkley W R Corp, Highbridge Capital Management, LLC., Fort Baker Capital Management LP, according to Nexqual as of June 11, 2026 at 02:17 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Berkley W R Corp | 7.83% |
| Highbridge Capital Management, LLC. | 7.48% |
| Fort Baker Capital Management LP | 6.62% |
| Aristeia Capital, LLC | 5.37% |
| Shaw D.E. & Co., Inc. | 4.95% |
| Tenor Capital Management Co., L.p. | 4.83% |
| AQR Arbitrage LLC | 4.71% |
| CrossingBridge Advisors, LLC | 4.49% |
Source: Nexqual, June 11, 2026 at 02:17 UTC.
From Roman Dbdr Acquisition Corp. Ii's Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the cybersecurity, artificial intelligence, or financial technology industries.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DMAA | Drugs Made In America Acquisiti | USD 10.61 | ▼ 0.14% |
| ATII | Archimedes Tech SPAC Partners I | USD 10.91 | ▼ 1% |
| HVII | Hennessy Capital Investment Cor | USD 10.43 | ▲ 0.1% |
| EGHA | EGH Acquisition Corp. | USD 10.3 | ▼ 0.1% |
| JACS | Jackson Acquisition Company II | USD 10.61 | ▼ 0.19% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 11, 2026 at 02:17 UTC. This page is informational and not investment advice.